Initiator Pharma A/S

As of June 30, 2026, Initiator Pharma A/S carries a market capitalization of 184.82M, placing it among publicly traded companies globally. Its enterprise value stands at 173.85M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Initiator Pharma A/S's next confirmed earnings release is scheduled for November 20, 2026.

As of June 30, 2026, Initiator Pharma A/S has 68.45M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Initiator Pharma A/S maintains a current ratio of 7.69, meaning it holds 7.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 113.59, indicating elevated leverage, while an interest coverage ratio of -245.92 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Initiator Pharma A/S posted a negative return on equity (ROE) of -336.22, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -162.71, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 1.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Initiator Pharma A/S recorded an income tax benefit of -4.46M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -46.26M and -41.80M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Initiator Pharma A/S's stock has declined approximately 24.83% over the past 52 weeks. The 50-day moving average sits at 2.23, while the 200-day moving average is 2.75.

Over the twelve months ended June 30, 2026, Initiator Pharma A/S generated - - in revenue and converted that into -41.80M in net income, yielding earnings per share of -0.61. EBITDA reached -47.74M, while operating income came in at -47.74M.

As of June 30, 2026, Initiator Pharma A/S holds 25.30M in cash and equivalents against 14.33M in total debt, resulting in a net debt position of -10.97M. Total book value stands at 12.61M, with working capital of 26.92M providing operational flexibility.

Initiator Pharma A/S produced -34.91M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -18.80: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -28.81, meaning Initiator Pharma A/S raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Initiator Pharma A/S's most recent stock split took place on July 2, 2021.

As of June 30, 2026, Initiator Pharma A/S has an Altman Z-Score of 2.09, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.